A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.

  title={A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.},
  author={Adriana Feder and Sara Costi and Sarah B. Rutter and Abigail B. Collins and Usha Govindarajulu and Manish Kumar Jha and Sarah R. Horn and Marin M. Kautz and Morgan Corniquel and Katherine A. Collins and Laura Bevilacqua and Andrew Glasgow and Jess W. Brallier and Robert H. Pietrzak and James W. Murrough and Dennis S. Charney},
  journal={The American journal of psychiatry},
OBJECTIVE Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors' previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. The present study is the first randomized controlled trial to test the efficacy and safety of repeated intravenous ketamine infusions for the… 

Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial

This clinical trial failed to find a significant dose-related effect of ketamine on PTSD symptoms, but secondary analyses suggested that the standard dose exerted rapid antidepressant effects.

Ketamine for Adults With Treatment-Resistant Depression or Post-Traumatic Stress Disorder

  • K. TranQ. Mahood
  • Psychology, Medicine
    Canadian Journal of Health Technologies
  • 2022
Overall safety and tolerability of ketamine for treatment of post-traumatic stress disorder or treatment-resistant depression is suggested, and most frequent side effects associated with ketamine were dissociative symptoms and cardiovascular changes such as increased blood pressure and heart rate, but these effects were transient.

Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders

These preliminary analyses suggest that acute ketamine may be broadly effective across treatment-resistant anxiety spectrum disorders and can be prolonged with maintenance treatment.

Pharmacotherapy for post traumatic stress disorder (PTSD).

The findings of this review support the conclusion that SSRIs improve PTSD symptoms; they are first-line agents for the pharmacotherapy of PTSD, based on moderate-certainty evidence.

Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder: Open-Label Single-Arm Pilot Study

Ekesketamine significantly improved depression symptoms, suggesting that it is likely to be a treatment of choice in this specific population of patients having TRD with comorbid PTSD.

The Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis

Ketamine was not effective on lower the PTSD incidence for soldiers on the battlefield, nor on the PTSD-scale scores in early PTSD patients, however, it may improve the Post-traumatic stress disorder (PTSD) scale scores for chronic conditions.

Evidence for the beneficial effect of ketamine in the treatment of patients with post-traumatic stress disorder: A systematic review and meta-analysis

Post-traumatic stress disorder (PTSD) is an anxiety disorder with manifestations somatic resulting from reliving the trauma. The therapy for the treatment of PTSD has limitations, between reduced

Ketamine-assisted psychotherapy for trauma-exposed patients in an outpatient setting: A clinical chart review study

Sublingual ketamine-assisted psychotherapy was associated with heterogenous clinical utility among patients with trauma-exposure in an outpatient setting and this study was underpowered and unrepresentative of the population of ketamine patients in the United States.

A Systematic Review of Neurocognitive Effects of Subanesthetic Doses of Intravenous Ketamine in Major Depressive Disorder, Post-Traumatic Stress Disorder, and Healthy Population

Ketamine administration among patients with depression and possibly with PTSD does not show significant impairment of cognitive functions in the short-term, in contrast with the immediate altered cognitive dysfunction found in healthy subjects.